Ketamine Telehealth: What Mindbloom, Joyous and Better U Actually Provide (And Where the Regulatory Risk Sits)
What is Ketamine Therapy?
Ketamine is a dissociative anaesthetic first synthesised in 1962 and used widely in clinical settings for procedural sedation and pain management. Since the early 2000s, a growing body of evidence has established its rapid-acting antidepressant properties — particularly for treatment-resistant depression (TRD), where conventional antidepressants and psychotherapy have failed. [2]
Esketamine (Spravato), the S-enantiomer of ketamine delivered as a nasal spray, received NICE approval for treatment-resistant depression in 2021 and is available through NHS specialist services in England. [3] Racemic ketamine (the compound itself) remains a Schedule 2 controlled drug in the UK — prescribable off-label by licensed clinicians but requiring strict handling and monitoring protocols.
The US telehealth ketamine market — where platforms like Mindbloom, Joyous, and Better U mail compounded ketamine lozenges to patients — operates under a substantially different regulatory structure and is not replicable in the UK under current MHRA and Home Office regulations.
Key Takeaways
- Ketamine has strong RCT evidence for treatment-resistant depression and suicidal ideation — rapid antidepressant response within 24–72 hours distinguishes it from all other antidepressant classes.
- In the UK, ketamine is a Schedule 2 controlled drug regulated by the Home Office and MHRA. Home-delivery ketamine models used by US platforms like Mindbloom are not permitted under UK regulations.
- Esketamine (Spravato) nasal spray is NICE-approved (TA693) for TRD and available through NHS specialist mental health services.
- US OIG Advisory Opinion 25-03 (2025) found that cash-pay-only ketamine telehealth services operating outside insurance reimbursement may avoid Anti-Kickback Statute liability — but this is a US regulatory ruling with no UK relevance.
- UK ketamine-assisted therapy is available via private ketamine clinics (Awakn Life Sciences, Numinus UK, and others) in supervised settings.
- Evidence tier: Tier 2 mechanistic — strong mechanistic and trial data for TRD; evidence for wellness applications in non-clinical populations is substantially weaker.
How Ketamine Works: Mechanism of Action
Ketamine’s primary mechanism is NMDA receptor antagonism. By blocking NMDA receptors (a subtype of glutamate receptor), it triggers a downstream cascade that includes:
- AMPA receptor activation — upregulation of AMPA receptors, which drives synaptogenesis.
- BDNF release — brain-derived neurotrophic factor, which is associated with synaptic plasticity and resilience.
- mTORC1 activation — paradoxically, in the brain, the same pathway rapamycin inhibits peripherally drives the synaptic growth associated with ketamine’s antidepressant effect.
This rapid synaptogenesis hypothesis explains ketamine’s distinctive time course: antidepressant effects can appear within 2–4 hours of administration and peak at 24–72 hours — far faster than conventional SSRIs/SNRIs, which require weeks of receptor adaptation.
The dissociative effects (altered perception, ego dissolution at higher doses) are often described as psychotherapeutically useful in ketamine-assisted psychotherapy (KAP) settings, where the altered state facilitates engagement with therapeutic material. [4]
Evidence: What the Research Shows
Treatment-resistant depression
The seminal Zarate et al. (2006) RCT established ketamine’s rapid antidepressant effect: a single IV infusion at 0.5 mg/kg produced significant antidepressant response within 110 minutes in TRD patients vs placebo. [2] This paper launched a decade of replication and extension studies.
Murrough et al. (2013, n=73) confirmed efficacy vs active control (midazolam), ruling out dissociative state as the sole mechanism. Response rate of 64% vs 28% for midazolam at 24 hours. [1]
Esketamine (NICE TA693)
NICE approved intranasal esketamine (Spravato) for adults with TRD who have not responded to ≥2 adequate antidepressant trials. The NICE-reviewed evidence (TRANSFORM trials) showed significantly greater remission rates vs continued antidepressant therapy alone. [3] NHS access requires referral to a specialist mental health service.
Suicidal ideation
Multiple studies show ketamine reduces acute suicidal ideation within hours — a unique property among antidepressants. This is the primary driver of its use in crisis settings.
Dosage and Protocol
| Route | Dose | Setting | UK availability |
|---|---|---|---|
| IV infusion | 0.5 mg/kg over 40 min | Clinic, monitored | Private clinics |
| Intranasal (esketamine) | 56–84 mg | Supervised clinic (NICE TA693) | NHS specialist + private |
| IM injection | 0.3–0.5 mg/kg | Clinic, monitored | Private clinics |
| Oral lozenge (compounded) | 100–400 mg | Not available via home delivery in UK | Off-label, clinic supervised only |
A standard KAP course in UK private practice typically involves 6–8 sessions over 4–8 weeks, with psychotherapeutic integration support. Sessions last 1–2 hours including monitoring. Cost: £400–800 per session at established UK clinics.
Safety, Side Effects, and Drug Interactions
Acute: Dissociation, dizziness, nausea, elevated blood pressure (BP monitoring mandatory during infusion). Psychological distress during session (rare with appropriate screening and support).
Repeated use risks: Ketamine-induced uropathy (bladder damage) — associated with heavy recreational use; rare at clinical doses with appropriate gaps between sessions. Dependence potential with frequent use.
Contraindications: Uncontrolled hypertension, active psychosis or mania, history of ketamine abuse, severe hepatic impairment. Pregnancy and breastfeeding.
Drug interactions: CNS depressants, benzodiazepines (additive sedation — manage carefully). MAOIs (contraindicated — hypertensive crisis risk).
UK Regulatory Status
Ketamine is a Class B controlled drug (Schedule 2) under the Misuse of Drugs Act 1971, reclassified from Class C in 2014 following concerns about recreational misuse. [6] It is regulated by the Home Office (for controlled drug scheduling) and MHRA (for prescribing and supply).
Key regulatory facts for UK patients:
- Ketamine cannot be dispensed for home use without specific Home Office authorisation — the US model of mailing compounded ketamine lozenges to patients is not legal in the UK.
- Esketamine (Spravato) nasal spray has full MHRA marketing authorisation for TRD and is NICE-approved for NHS use.
- Off-label IV or IM ketamine can be prescribed and administered by licensed clinicians in appropriate supervised settings.
- The FSA does not regulate ketamine — it is wholly within MHRA and Home Office scope.
How to Stack Ketamine Therapy with Other Protocols
Integration psychotherapy: The evidence for ketamine-assisted psychotherapy (KAP) suggests that psychotherapeutic sessions immediately following the altered state produce better and more durable outcomes than ketamine infusions without integration support. This is standard practice at UK KAP clinics.
Psilocybin-assisted therapy: Both modalities target neuroplasticity through different mechanisms. Combination protocols are experimental; no RCT data. Clinical caution warranted.
Standard antidepressants: Ketamine is typically used in patients who have not responded to standard antidepressants, not alongside them. Some protocols continue a maintenance SSRI/SNRI. Clinician-supervised — no self-directed stacking.
Microdosing: See our psilocybin and microdosing article for the evidence landscape on sub-perceptual psychedelic dosing.
Find a UK Ketamine Practitioner
UK ketamine-assisted therapy is available through licensed private clinics in London and other major cities. Services require a clinical assessment, appropriate screening, and a therapeutic framework.
Find a UK ketamine therapy specialist →
Frequently Asked Questions
Can I access Mindbloom, Joyous, or Better U from the UK? No — these are US services operating under US regulatory frameworks. Ketamine cannot legally be mailed to UK home addresses. UK patients must access ketamine therapy through licensed UK clinical services.
Is ketamine available on the NHS? Esketamine (Spravato) nasal spray is available through NHS specialist mental health services for qualifying TRD patients (≥2 failed antidepressant trials). IV ketamine is not routinely available on the NHS but may be used in specialist settings.
What’s the difference between ketamine and esketamine? Esketamine is the S-enantiomer (one mirror-image form) of racemic ketamine. It is more potent at NMDA receptors and is the licensed version for TRD. Racemic ketamine (the form used in IV infusions at most clinics) contains both R and S enantiomers.
How quickly does ketamine work for depression? Antidepressant effects typically appear within 24–72 hours of a single infusion — significantly faster than conventional antidepressants. Effects are often short-lived (days to weeks) without a structured repeat course or psychotherapeutic integration.
References
- Murrough JW, et al. Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression. Am J Psychiatry. 2013;170(10):1134–1142. PubMed 23982301
- Zarate CA Jr, et al. A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression. Arch Gen Psychiatry. 2006;63(8):856–864. PubMed 16894061
- NICE. Esketamine nasal spray (Spravato) for treatment-resistant depression. TA693. 2021. NICE TA693
- Dore J, et al. Ketamine Assisted Psychotherapy: Patient Demographics, Clinical Data and Outcomes. J Psychoactive Drugs. 2019;51(2):189–198. PubMed 30802186
- Schoevers RA, et al. Ketamine for depression: Where do we go from here? Psychiatry Res. 2016;246:535–545. PubMed 27837951
- MHRA / Home Office. Ketamine rescheduling to Class B. 2014. Home Office Circular 002/2014
- US OIG. Advisory Opinion 25-03. 2025. OIG AO-25-03
- Mandal S, et al. Efficacy of ketamine in treatment-resistant depression: a review. Indian J Psychol Med. 2019;41(2):99–105. PubMed 30983620